NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

Prior treatment

• Patients with known MSI-H or dMMR who were evaluated by investigators as suitable for treatment with immune checkpoint inhibitors.
• Patients allergic to the investigational drug and its excipients
• Received irinotecan before enrollment
• Had undergone surgery and other oncologic treatments within the first 4 weeks of enrollment
• Previous treatment-related toxicity didn't return to NCI-CTCAE v5.0 class I or below.
• The use of CYP3A, CYP2C8, and UGT1A1 inhibitors or inducers couldn't be discontinued or were not discontinued within 2 weeks prior to enrollment
• Tendency of arterial embolism and massive bleeding within 6 months before enrollment (except surgical bleeding)

Other illness

• Serious gastrointestinal disorders
• Interstitial lung disease
• Gastrointestinal perforation, intraperitoneal abscess, and fistula
• Any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, heart disease, active bleeding, active viral infection, etc
• Have had other malignancies within the past 5 years or currently, except cured cervical carcinoma in situ, uterine carcinoma in situ, and non-melanoma skin cancer

Age

• Patients of childbearing age who refuse to take contraceptives, women who are pregnant or breastfeeding

Other

• Underweight (body mass index \[BMI\]\<18.5 kg/m\^2
• Known or suspected central nervous system metastasis
• Patients with fluid accumulation that couldn't reach a stable state and small amount of pleural effusion or ascites on imaging without clinical symptoms could be enrolled
• Intestinal obstruction, or a risk of intestinal obstruction in the short term
• The researchers didn't consider it appropriate to participate in this study

• ≥18 years old
• Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma
• The unresectable stage of metastatic disease has not received any systemic antitumor therapy
• For subjects previously receiving neoadjuvant or adjuvant therapy, the date of first discovery of disease progression must be at least 12 months removed from the date of last administration of neoadjuvant or adjuvant therapy
• The presence of at least 1 measurable lesion that can be evaluated according to the RECIST v1.1 criteria
• ECOG 0\~1
• Normal bone marrow and organ function
• Understand the situation of this study, patients and/or legal representatives voluntarily agree to participate in this study and sign informed consent form